CONCLUSION AND RESULTS

During the 2 years of treatment with baricitinib, the VAS itching score had steadily decreased (Figure 2), and the patient reported significant improvement in itching and sleep quality after treatment, without any adverse effects. After discontinuation of baricitinib for 2 weeks, in July 2022, the patient returned to the clinic for reexamination, and the results indicated that the number of skin rashes on the outer side of both thighs had decreased by half, and the color had become dull, although some dark brown hyperpigmentation and scars remained on the extensor aspect of both lower legs. (Figure 1E and 1F). The results of regular reexaminations showed routine blood and urine with normal liver and kidney function and electrolytes. Currently, the patient is still under follow-up.